<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Human T cells genetically modified to express chimeric antigen receptors (CAR) specific to the B cell <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> antigen CD19 can successfully eradicate systemic human CD19(+) <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> in immunocompromised <z:mp ids='MP_0002536'>SCID</z:mp> (severe combined immunodeficient)-Beige mice </plain></SENT>
<SENT sid="1" pm="."><plain>However, in the clinical setting, CD4(+) CD25(hi) T regulatory cells (Treg) present within the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> microenvironment may be potent suppressors of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>-targeted effector T cells </plain></SENT>
<SENT sid="2" pm="."><plain>In order to assess the impact of Tregs on CAR-modified T cells in the <z:mp ids='MP_0002536'>SCID</z:mp>-Beige xenotransplant model, we isolated, genetically targeted and expanded natural T regulatory cells (nTreg) </plain></SENT>
<SENT sid="3" pm="."><plain>In vitro nTregs modified to express CD19-targeted CARs efficiently inhibited the proliferation of activated human T cells, as well as the capacity of CD19-targeted 19-28z(+) effector T cells to lyse CD19(+) Raji <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells </plain></SENT>
<SENT sid="4" pm="."><plain>Intravenous infusion of CD19-targeted nTregs into <z:mp ids='MP_0002536'>SCID</z:mp>-Beige mice with systemic Raji <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> traffic to sites of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> and recapitulate a clinically relevant hostile <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> microenvironment </plain></SENT>
<SENT sid="5" pm="."><plain>Antitumor efficacy of subsequently infused 19-28z(+) effector T cells was fully abrogated as assessed by long-term survival of treated mice </plain></SENT>
<SENT sid="6" pm="."><plain>Optimal suppression by genetically targeted nTregs was dependent on nTreg to effector T-cell ratios and in vivo nTreg activation </plain></SENT>
<SENT sid="7" pm="."><plain>Prior infusion of <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> in the setting of this nTreg-mediated hostile microenvironment was able to restore the antitumor activity of subsequently infused 19-28z(+) effector T cells through the eradication of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>-targeted nTregs </plain></SENT>
<SENT sid="8" pm="."><plain>These findings have significant implications for the design of future clinical trials utilizing CAR-based adoptive T-cell therapies of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> </plain></SENT>
</text></document>